Receptor News and Research

RSS

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Genomic Health, Inc. today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer.

12 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

Study may help in treating sex differentiation disorders in children

Is it a boy or a girl? Expecting parents may be accustomed to this question, but contrary to what they may think, the answer doesn't depend solely on their child's sex chromosomes.

11 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Scientists explore new potential therapies for Parkinson's disease

Following up on their previous work showing the rescue of dopamine neurons by chemicals that interact with the retinoid X receptor (RXR), researchers have now investigated the potential of these chemicals, known as RXR ligands, for the treatment of Parkinson's disease.

11 Dec 2009

Winners of the 2010 ASBMB-Merck Award

James A. Wells, professor and chairman of the department pharmaceutical chemistry at the University of California, San Francisco, and director of UCSF's small molecule discovery center, has been named the winner of the 2010 American Society for Biochemistry and Molecular Biology-Merck Award for his pioneering studies in the field of protein engineering.

11 Dec 2009

Researchers find weakness in H1N1's method for evading detection by immune system

Researchers at Rice University and Baylor College of Medicine (BCM) have found what they believe is a weakness in H1N1's method for evading detection by the immune system.

11 Dec 2009

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Chemotherapy generally improves survival in postmenopausal breast cancer patients, according to a landmark study led by Dr. Kathy Albain of Loyola University Health System.

11 Dec 2009

Positive results from Genomic Health's Oncotype DX study in breast cancer patients with node-positive disease

Genomic Health, Inc. today announced that The Lancet Oncology published positive results from a study of Oncotype DX(®) in postmenopausal women with node-positive, estrogen receptor-positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute-supported clinical trials cooperative group.

11 Dec 2009

Initiation of multi-national Phase III study of Stimuvax announced

Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).

11 Dec 2009

Women with high BMI are at increased risk of dying from breast cancer

Breast cancer patients with a high body mass index (BMI) have a poorer cancer prognosis later in life. Specifically, their treatment effect does not last as long and their risk of death increases.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Soyfood consumption linked to decreased risk of breast cancer, finds study

A major new study published in the Journal of the American Medical Association (JAMA) finds that women with breast cancer would be well-served by including soyfoods in their daily diet. Soyfood consumption was significantly linked to a decreased risk of death and cancer recurrence among the breast cancer patients in this study.

11 Dec 2009

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.

10 Dec 2009

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

10 Dec 2009

Receptor News and Research

Pfizer announces results from studies evaluating neratinib

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Texas researchers identify new detection method for circulating tumor cells

Findings from three studies using bioTheranostics' breast cancer molecular test reported

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Study may help in treating sex differentiation disorders in children

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Scientists explore new potential therapies for Parkinson's disease

Winners of the 2010 ASBMB-Merck Award

Researchers find weakness in H1N1's method for evading detection by immune system

Chemotherapy improves overall survival in postmenopausal breast cancer patients

Positive results from Genomic Health's Oncotype DX study in breast cancer patients with node-positive disease

Initiation of multi-national Phase III study of Stimuvax announced

Women with high BMI are at increased risk of dying from breast cancer

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Soyfood consumption linked to decreased risk of breast cancer, finds study

Targacept commences TC-5619 Phase 2 study of cognitive dysfunction in schizophrenia

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News